Antifungals Market Forecast 2026–2035 presenting data insights and patterns

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Antifungals Market During 2026–2030?

The antifungals market size has seen robust growth in recent years. This market is projected to expand from $29.6 billion in 2025 to $31.98 billion in 2026, driven by a compound annual growth rate (CAGR) of 8.1%. Several factors contributed to its historical growth, including an increase in hospital-acquired infections, the widespread adoption of azoles, a growing immunosuppressed population, the availability of established antifungal therapies, and the global prevalence of mycoses.

The antifungals market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $44.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. The anticipated growth during this period stems from factors such as an increase in systemic fungal infections, worries about antifungal resistance, a need for safer treatments, the expansion of hospital services, and improved diagnosis rates. Key trends foreseen for the same period encompass a higher incidence of fungal infections, an escalating need for broad-spectrum antifungal agents, the proliferation of topical antifungal remedies, greater application in individuals with compromised immune systems, and the emergence of new classes of antifungal drugs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2442&type=smp

What Drivers Are Expected To Influence The Antifungals Market During The Forecast Period?

The expanding prevalence of fungal infections is anticipated to boost the antifungals market going forward. Fungal infections are illnesses resulting from fungi invading and multiplying within or on the body, affecting various regions such as the skin, nails, lungs, and mucous membranes. The rising incidence of these infections is attributed to climate change creating conditions that encourage fungi to spread and adapt to elevated temperatures, thereby increasing human exposure and infection risks. Antifungals are essential for treating fungal diseases by inhibiting the growth and reproduction of fungi, either by disrupting their cell wall or membrane, blocking vital enzymatic processes, or interfering with their ability to synthesize crucial components, which in turn reduces the fungal load, alleviates symptoms, and prevents the infection from spreading throughout the body. For instance, in May 2025, according to the UK Health Security Agency, a UK-based government department, bloodstream infections caused by yeast increased by 4% in 2024 compared with 2023, rising from 2,170 reported cases to 2,247. Thus, the growing occurrence of fungal infections is propelling the growth of the antifungals market.

How Are The Various Segments Of The Antifungals Market Categorized?

The antifungals market covered in this report is segmented –

1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines

2) By Route of Administration: Oral, Parenteral, Topical

3) By End users: Hospitals & Clinics, Dermatology clinics, Other Users

Subsegments:

1) By Echinocandins: Caspofungin, Micafungin, Anidulafungin

2) By Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole

3) By Polyenes: Amphotericin B, Nystatin

4) By Allylamines: Terbinafine, Naftifine

What Trends Are Affecting The Expansion Of The Antifungals Market?

Leading companies within the antifungals market are prioritizing advancements in product design and formulation, including the development of long-acting echinocandin therapies. This focus aims to enhance patient compliance, decrease the frequency of drug administration, and satisfy pressing clinical requirements for invasive fungal infections. Through the extension of drug half-life and alterations to pharmacokinetics, these contemporary antifungals provide efficient fungal control alongside more user-friendly dosing regimens. A notable example occurred in March 2023 when Cidara Therapeutics, a US-based biotechnology firm, in collaboration with Melinta Therapeutics (U.S.), declared that REZZAYO (rezafungin for injection) had received FDA approval for managing candidemia and invasive candidiasis. Rezafungin, a once-weekly echinocandin, demonstrated non-inferior efficacy when contrasted with daily caspofungin in the ReSTORE Phase 3 clinical trials, all while exhibiting a similar safety profile. The potential for extended dosing offered by REZZAYO addresses a significant deficiency in current antifungal treatments, thereby fostering improved continuity of care and alleviating the burden on hospitals in acute-care environments.

Which Major Firms Influence Developments In The Antifungals Market?

Major companies operating in the antifungals market are Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

Read the full antifungals market report here:

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Which Region Is Forecast To Lead The Antifungals Market In Terms Of Market Size?

North America was the largest region in the drugs for antifungals market in 2025. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Antifungals Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2442&type=smp

Browse Through More Reports Similar to the Global Antifungals Market 2026, By The Business Research Company

Antifungals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report

Fungicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/fungicides-global-market-report

Candidiasis Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795